CC

Chemours is a cyclical performance-chemicals maker (refrigerants, TiO2 pigment, fluoropolymers) trading at just 0.5x sales and a $3.04B market cap, which looks optically cheap. But the fundamentals are weak and the balance sheet is fragile: FY2025 revenue was flat at $5.81B (+0.4%) while gross profit fell 21% to $902M (15.5% gross margin), and the company swung to a -$386M net loss (-$2.57 diluted EPS) from +$69M a year earlier. A large chunk of that loss is the non-cash $181M valuation allowance against U.S./foreign/state deferred tax assets — itself a red flag, because it signals management doubts it will generate enough future taxable income to use those assets. ROE is -68.2% on a razor-thin $566M of equity against $6.81B of liabilities (12.03x), and long-term debt sits at $4.07B versus $670M cash.

The offsetting bull points are real but speculative. Operating cash flow more than doubled to $264M and capex was cut 41% to $213M, so the business still generated modestly positive free cash flow despite the GAAP loss. The pending ~$360M Taiwan land sale (Kuan Yin, expected to close by mid-2026) is earmarked for debt reduction, and Amendment No. 4 pushed the $1,050M term-loan maturity out to October 2032 — both ease near-term refinancing pressure. Cost actions (idling a northern Florida TiO2 mine, shifting to a third-party earth-mover) target cash generation.